Quantcast

FDA OKs first treatment for breast cancer with a certain inherited genetic mutation

The FDA has expanded the use of AstraZeneca’s Lynparza, the treatment for certain types of breast cancer patients, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer.

The expanded approval is for patients with certain types of breast cancer that have spread and whose tumors have a specific inherited genetic mutation. It is also the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx. The approval of the BRACAnalysis CDx was granted to Myriad Genetic Laboratories, Inc.

“This class of drugs has been used to treat advanced, BRCA-mutated ovarian cancer and has now shown efficacy in treating certain types of BRCA-mutated breast cancer,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “This approval demonstrates the current paradigm of developing drugs that target the underlying genetic causes of a cancer, often across cancer types.”

Breast cancer is the most common form of cancer in the United States. The National Cancer Institute at the National Institutes of Health estimates approximately 252,710 women will be diagnosed with breast cancer this year, and 40,610 will die of the disease. Approximately 20-25 percent of patients with hereditary breast cancers and 5-10 percent of patients with any type of breast cancer have a BRCA mutation. BRCA genes are involved with repairing damaged DNA and normally work to prevent tumor development. However, mutations of these genes may lead to certain cancers, including breast cancers.

 

Leave a Reply

Your email address will not be published. Required fields are marked *